APOA2 and coronary artery disorder: Clinical trials in patients whose primary lipid abnormality is a low HDL-cholesterol level revealed a reduced incidence of coronary artery disease events after therapy using gemfibrozil, an agonist of PPARα that increases the expression of numerous genes involved in lipid metabolism, including apoA-II and apoA-I [89,90].